Oncology Research最新文献_第2页

Retraction: Downregulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16. 撤回：通过靶向 TRIM16 下调 microRNA-135 可提高非小细胞肺癌对吉非替尼的敏感性。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.056888

引用次数: 0

Retraction: Long noncoding RNA GAS5 promotes proliferation, migration, and invasion by regulation of miR-301a in esophageal cancer. 撤回：长非编码 RNA GAS5 通过调控 miR-301a 促进食管癌的增殖、迁移和侵袭

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.056896

引用次数: 0

Epidemiological and clinical characteristics of lung cancer in Saudi Arabia: a retrospective study in single oncology center. 沙特阿拉伯肺癌的流行病学和临床特征：对单个肿瘤中心的回顾性研究。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.052358

Yousef Katib, Nasser Mulla

{"title":"Epidemiological and clinical characteristics of lung cancer in Saudi Arabia: a retrospective study in single oncology center.","authors":"Yousef Katib, Nasser Mulla","doi":"10.32604/or.2024.052358","DOIUrl":"https://doi.org/10.32604/or.2024.052358","url":null,"abstract":"Background: Lung cancer (LC) is one of the most common neoplastic diseases and a leading cause of death in Saudi Arabia. Its incidence in Saudi Arabia has increased by more than 3% within two decades. Our study aimed to describe the epidemiological and genetic landscapes of LC in Al-Madinah city in Saudi Arabia.Methods: A retrospective analysis was conducted on the medical records of 65 patients diagnosed with lung cancer between 2015 and 2021 at a single medical oncology center in Al-Madinah city of Saudi Arabia.Results: The mean patients' age was 59.2 years, with 50 (76.9%) males and 15 (23.1%) females; 37 (57%) smokers, and 28 (43%) non-smokers. The number of cases per year has increased gradually over six years from 2015 (n = 3) to 2020 (n = 13). The most prevalent histopathological diagnosis was non-small cell lung cancer (NSCLC) (n = 58, 89%) followed by small cell lung cancer (SCLC) (n = 5, 7.8%). NSCLC was frequently more common in smokers while squamous cell carcinoma was more frequent in non-smokers. Around 89% (n = 58) of the cases were diagnosed in late stage IV and the most common metastatic sites were to pleura and lymph nodes (n = 32, 49.2%). Program Death Legend-1 (PDL-1) was fairly expressed in 7/10 (70%) patients. Epidermal Growth Factor Receptor (EGFR) was mutated in 5/17 (29%) patients. Other mutations detected include Anaplastic Lymphoma Kinase (ALK) and phosphatidylinositol 3-kinase (PIK3C) mutations in two patients.Conclusions: Our study revealed that lung cancer is a significant burden in Al-Madinah city of Saudi Arabia. If the risk factors are not controlled, the number of cases may increase considerably. Health education about the risk factors and cancer prevention helps in early lung cancer detection.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 11","pages":"1803-1809"},"PeriodicalIF":2.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro. 揭示治疗潜力：KBU2046 通过限制 TGF-β1 在体外的激活来阻止三阴性乳腺癌细胞的迁移。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.049348

Jinxia Chen, Suli Dai, Geng Zhang, Sisi Wei, Xuetao Zhao, Yang Zheng, Yaojie Wang, Xiaohan Wang, Yunjiang Liu, Lianmei Zhao

{"title":"Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro.","authors":"Jinxia Chen, Suli Dai, Geng Zhang, Sisi Wei, Xuetao Zhao, Yang Zheng, Yaojie Wang, Xiaohan Wang, Yunjiang Liu, Lianmei Zhao","doi":"10.32604/or.2024.049348","DOIUrl":"10.32604/or.2024.049348","url":null,"abstract":"Background: Triple-negative breast cancer (TNBC) is a heterogeneous, recurring cancer characterized by a high rate of metastasis, poor prognosis, and lack of efficient therapies. KBU2046, a small molecule inhibitor, can inhibit cell motility in malignant tumors, including breast cancer. However, the specific targets and the corresponding mechanism of its function remain unclear.Methods: In this study, we employed (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H tetrazolium) (MTS) assay and transwell assay to investigate the impact of KBU2046 on the proliferation and migration of TNBC cells in vitro. RNA-Seq was used to explore the targets of KBU2046 that inhibit the motility of TNBC. Finally, confirmed the predicted important signaling pathways through RT-qPCR and western blotting.Results: In this study, we found that KBU2046 functioned as a novel transforming growth factor-β (TGF-β1) inhibitor, effectively suppressing tumor cell motility in vitro. Mechanistically, it directly down-regulated leucine-rich repeat-containing 8 family, member E (LRRC8E), latent TGFβ-binding protein 3 (LTBP3), dynein light chain 1 (DNAL1), and MAF family of bZIP transcription factors (MAFF) genes, along with reduced protein expression of the integrin family. Additionally, KBU2046 decreased phosphorylation levels of Raf and ERK. This deactivation of the ERK signaling pathway impeded cancer invasion and metastasis.Conclusions: In summary, these findings advocate for the utilization of TGF-β1 as a diagnostic and prognostic biomarker and as a therapeutic target in TNBC. Furthermore, our data underscore the potential of KBU2046 as a novel therapeutic strategy for combating cancer metastasis.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 11","pages":"1791-1802"},"PeriodicalIF":2.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative bioinformatics and in vitro exploration of EVI2A expression: unraveling its immunological and prognostic implications in kidney renal clear cell carcinoma. EVI2A 表达的综合生物信息学和体外探索：揭示其在肾透明细胞癌中的免疫学和预后意义。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.050851

Rong Liu, Sheng Li, Situ Xiong, Fucun Zheng, Xiangpeng Zhan, Jin Zeng, Bin Fu, Songhui Xu, Shaoxing Zhu, R U Chen

{"title":"Integrative bioinformatics and in vitro exploration of EVI2A expression: unraveling its immunological and prognostic implications in kidney renal clear cell carcinoma.","authors":"Rong Liu, Sheng Li, Situ Xiong, Fucun Zheng, Xiangpeng Zhan, Jin Zeng, Bin Fu, Songhui Xu, Shaoxing Zhu, R U Chen","doi":"10.32604/or.2024.050851","DOIUrl":"10.32604/or.2024.050851","url":null,"abstract":"EVI2A has emerged as a significant biomarker in various diseases; however, its biological role and mechanism in kidney renal clear cell carcinoma (KIRC) remains unexplored. We used TCGA and GEO databases to analyze EVI2A gene expression comprehensively and performed pan-cancer assessments. Clinical relevance was evaluated through Kaplan-Meier analysis and ROC curves. The gene's immune relevance was explored through analyses of the tumor microenvironment (TME), Tumor Immune Single-cell Hub (TISCH), immune checkpoints, and immunotherapy sensitivity. Our results indicate that EVI2A expression is upregulated in KIRC, showing correlations with tumor grade and T/N/M stage. EVI2A demonstrates high diagnostic accuracy (AUC=0.906) and predicts poor overall and progression-free survival in KIRC patients. Furthermore, EVI2A expression exhibits significant associations with immunity, including TME scores and specific immune cell types such as Tfh cells, CD4 memory T cells, and CD8+ T cells. Elevated EVI2A expression suggests increased sensitivity to PD-1/CTLA-4 and tyrosine kinase inhibitors. In vitro assays confirmed the impact of EVI2A on KIRC behavior, with its knockdown resulting in reduced cell proliferation and migration. In conclusion, our comprehensive analysis identifies EVI2A as a promising biomarker and a novel therapeutic target for intervening in KIRC. These findings hold significant implications for further research and potential clinical applications.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 11","pages":"1733-1746"},"PeriodicalIF":2.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Remodeling tumor microenvironment using pH-sensitive biomimetic co-delivery of TRAIL/R848 liposomes against colorectal cancer. 利用 pH 值敏感的生物仿生联合递送 TRAIL/R848 脂质体重塑肿瘤微环境，对抗结直肠癌。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.045564

Yongjian Huang, Jinzhou Wang, Jiuhua Xu, Ning Ruan

{"title":"Remodeling tumor microenvironment using pH-sensitive biomimetic co-delivery of TRAIL/R848 liposomes against colorectal cancer.","authors":"Yongjian Huang, Jinzhou Wang, Jiuhua Xu, Ning Ruan","doi":"10.32604/or.2024.045564","DOIUrl":"10.32604/or.2024.045564","url":null,"abstract":"Background: Despite significant advancements in the development of anticancer therapies over the past few decades, the clinical management of colorectal cancer remains a challenging task. This study aims to investigate the inhibitory effects of cancer-targeting liposomes against colorectal cancer.Materials and methods: Liposomes consisting of 3β-[N-(N', N'-dimethylamino ethane)carbamoyl]-cholesterol (DC-CHOL), cholesterol (CHOL), and dioleoylphosphatidylethanolamine (DOPE) at a molar ratio of 1:1:0.5 were created and used as carriers to deliver an apoptosis-inducing plasmid encoding the tumor necrosis factor-related apoptosis-inducing ligand (pTRAIL) gene, along with the toll-like receptor (TLR7) agonist Rsiquimod (R848). The rationale behind this design is that pTRAIL can trigger cancer cell apoptosis by activating the DR4/5 receptor, while R848 can stimulate the immune microenvironment.Results: Experimental results demonstrated the synergistic effects of R848 and pTRAIL encapsulated by liposomes (RTL) in suppressing the proliferation of colorectal cancer cells. Moreover, further in vivo investigations revealed the strong anti-tumor efficacy of RTL in xenograft and orthotropic in situ models of colorectal cancer.Conclusions: These findings collectively highlight the therapeutic potential of R848/pTRAIL-loaded liposomes in the treatment of colorectal cancer.","PeriodicalId":19537,"journal":{"name":"Oncology Research","volume":"32 11","pages":"1765-1776"},"PeriodicalIF":2.0,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11497182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: MicroRNA-1277 inhibits proliferation and migration of hepatocellular carcinoma HepG2 cells by targeting and suppressing BMP4 expression and reflects the significant indicative role in hepatocellular carcinoma pathology and diagnosis after magnetic resonance imaging assessment. 撤回：MicroRNA-1277 通过靶向抑制 BMP4 的表达，抑制肝癌 HepG2 细胞的增殖和迁移，在肝癌病理和磁共振成像评估诊断中具有重要的指示作用。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.056904

引用次数: 0

Redefining the tumor microenvironment with emerging therapeutic strategies. 用新兴治疗策略重新定义肿瘤微环境。

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.055161

Suling Xu, Xiao Li, Wenxue Ma

引用次数: 0

Retraction: Long noncoding RNA urothelial carcinoma-associated 1 promotes the proliferation and metastasis of human lung tumor cells by regulating MicroRNA-144. 撤回：长非编码 RNA 尿道癌相关 1 通过调控 MicroRNA-144 促进人类肺肿瘤细胞的增殖和转移

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.056897

引用次数: 0

Retraction: MicroRNA-374a promotes hepatocellular carcinoma cell proliferation by targeting mitogen-inducible gene 6 (MIG-6). 撤回：MicroRNA-374a通过靶向有丝分裂原诱导基因6（MIG-6）促进肝癌细胞增殖

IF 2 4区医学

Oncology Research Pub Date : 2024-10-16 eCollection Date: 2024-01-01 DOI: 10.32604/or.2024.056902

引用次数: 0